Horizon Therapeutics (HZNP) Tops Q2 EPS by 74c; Raises Outlook

Horizon Therapeutics (NASDAQ: HZNP) reported Q2 EPS of $1.62, $0.74 better than the analyst estimate of $0.88. Revenue for the quarter came in at $832.5 million versus the consensus estimate of $685.03 million.

“Driving our record second-quarter performance was our highly successful TEPEZZA relaunch, which allowed Thyroid Eye Disease patients to rapidly access therapy and resulted in an increase in our full-year expectations,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “Our increased full-year net sales and adjusted EBITDA guidance represents strong double-digit year-over-year growth driven by TEPEZZA, KRYSTEXXA and our other rare disease medicines, where we are seeing continued strong underlying demand given the significant benefits our medicines provide to patients. We also initiated three clinical trials and acquired a biologics drug product manufacturing facility to support our strategy to maximize our key growth drivers, expand our pipeline and build a global presence. Horizon remains one of the fastest-growing biotechnology companies, underscoring our commitment to generate value for patients and our shareholders.”

GUIDANCE:

Horizon Therapeutics sees FY2021 revenue of $3.025-3.125 billion, versus the consensus of $2.81 billion.

For earnings history and earnings-related data on Horizon Therapeutics (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M